Background and Aims: B-cell lymphoma / leukemia (BCL)-10 and reactive oxygen species
Introduction
Lipopolysaccharide (LPS), a structural component of the outer envelope of all gramnegative bacteria, has three distinct domains. These include: 1) the highly conserved Lipid A domain composed of a phosphorylated glucosamine disaccharide backbone with multiple hydrophobic fatty acids; 2) a core oligosaccharide attached to Lipid A; and 3) the O-antigen, a variable polysaccharide side chain that extends from the core oligosaccharide and confers antigenic specificity to LPS from different bacteria. LPS is released into the circulation from the surface of gram-negative bacteria, alone or in association with other endogenous factors, and induces an intense inflammatory response, mediated by the toll-like receptor 4 (TLR4) in human colonic epithelial cells [1] [2] [3] [4] [5] .
Nuclear Factor (NF)-κB is a key determinant of the intestinal epithelial inflammatory reactions in response to LPS and occupies a central role in the transcriptional activation of proinflammatory genes. The involvement of B-cell lymphoma/leukemia (BCL)-10 in the activation of NFκB has been very well documented in lymphocytes and macrophages, and translocations involving BCL10 are associated with the constitutive activation of NFκB in the MALT (mucosa-associated lymphoid tumor) lymphomas [6] [7] [8] [9] [10] . BCL10 has also been implicated in gastric stromal tumors, not associated with Helicobacter pylori [11, 12] . BCL10, like nucleotide-binding oligomerization domain containing 2 (NOD2), which is an intracellular pattern recognition receptor protein that is associated with genetic predisposition to Crohn's Disease, has a caspase recruitment domain (CARD).
Recent studies have demonstrated that Bcl10 is a critical mediator in the activation of LPS, carrageenan, and platelet-activating factor (PAF)-induced inflammation in human colonic epithelial cells [13] [14] [15] , angiotensin II-induced inflammation in hepatocytes [16] , lysophosphatidic acid-induced activation of NF-B in murine embryonic fibroblasts [17] , and Gprotein-coupled receptor mediated activation of NF-κB in human embryonic 293 kidney cells [18] . Bcl10 has been identified by several different names in early reports, including CIPER, cCARMEN, c-E10, mE10, and hCLAP [19] . Previously, we reported that LPS activated NF-κB by two distinct pathways in human colonic epithelial cells: a toll-like receptor (TLR)-4-BCL10 pathway and a reactive oxygen species (ROS)-Heat shock protein (Hsp)27 pathway [20] . These cascades were integrated at the level of the IκB kinase (IKK) signalosome, leading to the phosphorylation and ubiquitination of IκBα and the nuclear translocation of NF-κB p65. LPS stimulated both of these pathways in the human and mouse tissues and cell lines that were studied, and the complete abrogation of NF-κB p65 activation required inhibition of both cascades.
The non-canonical pathway of NFκB activation, when elucidated in relation to TNFα, involved stimulation through the TNF-receptor with subsequent effects on TNF-receptor associated factors (TRAFs), including the ubiquitination of TRAF2. Reactions proceeded to induce increased NFκB-inducing kinase (NIK), phosphorylation of IκB-inducing kinase (IKK)-α, and NFκB cytoplasmic processing leading to the nuclear translocation of RelB and p52. These latter steps contrast with the canonical (RelA) activation that involves IKKβ phosphorylation, leading to the phosphorylation and subsequent ubiquitination of IκBα, and the nuclear translocation of RelA (p65) and p50 [21] [22] [23] .
Previously, LPS was implicated in NFκB activation by the non-canonical pathway, as well as the canonical pathway, but the mechanism by which this proceeded was not precisely clarified, since LPS produced no increase in total NIK, and an effect of LPS on phospho-NIK has not previously been demonstrated [24, 25] . In this report, we present new findings that demonstrate LPS activation of the non-canonical pathway of NFκB activation in human colonic epithelial cells, leading to increased nuclear RelB and p52. This cascade involves phosphorylations of BCL10 Ser 138 and NFκB-inducing kinase (NIK). By studies in mouse embryonic fibroblasts (MEF), in which either IKKα or IKKβ has been selectively knocked out, distinct LPS effects mediated by either IKKα or IKKβ are defined. Since endotoxin has such a critical role in sepsis and in the systemic inflammatory response syndrome, these findings may lead to new approaches to prevention and treatment of LPS-induced morbidity and mortality, as well as to increased understanding of mechanisms of intestinal inflammation.
Materials and Methods

Cell Culture
NCM460 is a nontransfected human colonic epithelial cell line, originally derived from the normal colonic mucosa of a 68-year-old Hispanic male. NCM460 cells were obtained and expanded in M3:10 media (INCELL, San Antonio, TX) [26] . The cells were maintained at 37°C in a humidified, 5% CO 2 environment with media exchanges at two day intervals. Confluent cells in T-25 flasks (Costar, Cambridge, MA) were harvested by trypsinization and subcultured in multiwell tissue culture clusters (Costar). Cells were treated with LPS (10 ng/ml; Sigma Chemical Company, St. Louis, MO) for 6 hours. At the end of the treatment, the spent media were collected from control and treated wells and stored at -80°C until further analysis. Cells were harvested by scraping, and cell lysates were prepared and stored at -80°C. Total cell protein was measured by BCA protein assay kit (Pierce, Rockford, IL), using bovine serum albumin as the standard.
Mouse embryonic fibroblasts (MEF), including wild type (WT), IKKα -/-and IKKβ -/-were a generous gift from Dr. Michael Karin's laboratory (University of California, San Diego).
These cell lines were developed from transgenic homozygous mice in which IKKα and IKKβ genes were deleted [27] . The WT, IKKα -/-and IKKβ -/-cells were grown in Dulbecco's modified
Eagle's medium with 10% fetal bovine serum. The cells were maintained and treated with LPS, using similar procedures as with the NCM460 cells.
Inhibition of TLR4-mediated pathway by blocking antibody
NCM460 cells were grown in 12-well tissue culture plates. When 70 -80% confluent, the cells were treated for 2 h with fresh media containing 20 μg/ml TLR4 receptor-blocking antibody (HTA-125; BioLegend, San Diego, CA) or IgG2α prior to LPS exposure for 6 h. Cells were incubated at 37°C in a humidified 5% CO 2 environment. After 6h, the extent of NIK phosphorylation was determined by FACE assay (see below).
BCL10 mRNA Silencing
Small interfering (si) RNA for BCL10 was procured (Qiagen, Valencia, CA), and BCL10 expression was silenced as described previously [13] . Cells were grown to 60-70% confluency in 12-well tissue culture plates, and the medium of the growing cells was aspirated and replaced with 1. The secretion of IL-8 in the spent medium of control and treated NCM460 cells was measured by a commercial ELISA kit for human IL-8 (R&D Systems, Minneapolis, MN), as described previously [13] . KC, the mouse homolog of IL-8, was measured in the spent medium of embryonic fibroblasts by a commercial ELISA (R&D Systems) [13] . Values were extrapolated from standard curves and normalized by the total cell protein concentrations, and expressed as pg/mg protein.
Expression of BCL10 protein in control and LPS-treated NCM460 and embryonic fibroblasts was determined by a solid-phase ELISA, previously developed by our laboratory for quantitative determination of BCL10 [28] . Nuclear extracts were prepared from treated and control cells using a nuclear extraction kit (Active Motif, Carlsbad, CA). Activated NFκBs (RelA, RelB, p52, or p50) in the samples were measured by oligonucleotide-based ELISA (Active Motif) [29] . Treated and control samples were incubated in wells of a 96-well microtiter plate that were coated with the NF-κB consensus nucleotide sequence (5-GGGACTTTCC-3). NF-κB from the cell samples attached to the wells and was captured by specific antibody to either RelA, RelB, p50, or p52. Binding of the specific NFκB family member was then detected by an anti-rabbit-HRP-conjugated IgG. Color developed with hydrogen peroxide/TMB chromogenic substrate, and intensity of the developed color was proportional to the quantity of RelA, RelB, p50, or p52 in each sample. The specificity of the binding to the nucleotide sequence was ascertained by pre-mixing of either free consensus nucleotide or mutated nucleotide to the sample before adding the cell preparation to the well. 
Measurement of phospho-BCL10 by FACE Assay
Phosphorylation of BCL10 in control and LPS-treated cells was measured by a fastactivated cell-based (FACE) ELISA (Active Motif) [29] . Control and treated cells were fixed with 4% formaldehyde and then washed. Cellular peroxide activity was quenched by addition of quenching buffer that contains PBS with H 2 O 2, and the non-specific binding was blocked by blocking buffer (Active Motif). Phospho-BCL10 was captured by a specific monoclonal phospho-BCL10 antibody (Ser138, sc-81484; Santa Cruz Biotechnology (SCBT), Santa Cruz, CA), and detected by anti-mouse-IgG-HRP (SCBT) and hydrogen peroxide-TMB substrate.
Measurement of phospho-NIK by FACE Assay
Total and phospho-NIK in control and LPS-treated NCM460 and embryonic fibroblasts were measured by FACE ELISA (Active Motif) [29] . A primary rabbit polyclonal antibody for NIK [sc-7211; SCBT] against the epitope AA:700-947 and a primary polyclonal goat antibody for phospho-NIK (sc-12957; SCBT) that recognized Thr 559 phosphorylation were used to determine the extent of NIK phosphorylation. Measurements of optical density were compared between control and treated samples and the data are expressed as % control.
Site-directed mutagenesis
To ascertain the role of serine-138 and serine-218 of the Bcl10 protein in mediating its functional effects, site-directed mutagenesis was performed to generate mutant Bcl10 proteins, in which one of the serine residues was changed to glycine (S138G or S218G), using the QuickChange Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA), according to the manufacturer's instructions. Mutations were confirmed by sequencing. The following mutant oligonucleotides were used to insert the mutations (underlined letters indicate mutated residues):
for M1 (S138G), 5′-CTCTCCAGATCAAATGGAGATGAGAGTAATTTC-3′; for M2 (S218G), 5′-GGAACTTGTGCAAACGGTAGTGAGATGTTTCTT-3′.
Confocal microscopy for imaging of NIK and phospho-NIK
NCM460 cells were grown in four-chamber tissue culture slides for 24h, and then treated with LPS 10 ng/ml for 6h. Methods for staining and examining cells by confocal microscopy were described previously [30] . Cells were washed once in 1×phosphate-buffered saline (PBS) Preparations were washed thoroughly and mounted with mounting medium containing DAPI (Vectashield®, Vector Laboratories, Inc., Burlingame, CA) for nuclear DNA staining, and observed using a Zeiss LSM 510 laser-scanning confocal microscope. Excitation was at 488 and 534 nm from an argon/krypton laser and at 361 nm from a UV laser. Green and red fluorescence were detected through LP505 and 585 filters. The fluorochromes were scanned sequentially, followed by export of the collected images using Zeiss LSM Image Browser software for analysis and reproduction.
Statistics
Data presented are the mean ± standard deviation (SD) of at least three biological samples with technical replicates of each sample. Unless stated otherwise in the text or figure legend, statistical significance was determined by one way analysis of variance (ANOVA), followed by a post-hoc Tukey-Kramer test for multiple comparisons using InStat3 software (GraphPad, La Jolla, CA). A p-value <0.05 is considered statistically significant. In the figures, *** indicates p<0.001, ** p<0.01, and * p<0.05. Error bars indicate SD.
Results
LPS-induced increases in nuclear
RelA, RelB, p50, and p52 were reduced by silencing BCL10 in human colonic epithelial cells NCM460 cells were exposed to LPS from E. coli (10 ng/ml x 6 hours), and effects on nuclear NF-κB family members RelA (p65), RelB, p50, and p52 were measured. LPS increased both nuclear RelA and RelB, to 3.8 and 1.8 times the baseline values, respectively (p<0.001) (Fig. 1A) . BCL10 silencing reduced the LPS-induced increase in RelA (to 2.2 times baseline) and eliminated the increase in RelB completely (p<0.001). Corresponding to the change in RelA, p50 increased to 3.9 times baseline and declined to 2.2 times baseline following BCL10
silencing. In parallel fashion, changes in p52 corresponded to those in RelB, increasing to two times baseline with LPS exposure, and returning to baseline wihen BCL10 was silenced. These results demonstrate that BCL10 is required for LPS-induced effects on mediators of both canonical (RelA and p50) and non-canonical (RelB and p52) pathways of NFκB acdtivation.. In contrast, LPS exposure did not increase nuclear RelA or p50 in the IKKβ −/− cells, but RelB and p52 both increased to ~two times the baseline value (p<0.001) (Fig. 1D) . Bcl10 silencing completely inhibited the LPS-induced increase in nuclear RelB and p52 in the IKKβ −/− cells.
Differential effects of
In the IKKα -/-cells, LPS did not induce an increase in RelB or p52 (Fig. 1C) . RelB and p52 increased to ~two times the baseline level in the WT MEF cells, and these increases were completely inhibited by Bcl10 knockdown by siRNA (Fig. 1B) , as in the IKKβ -/-cells. These findings demonstrate dependence on the presence of IKKα, and are consistent with the involvement of IKKα in the non-canonical pathway.
LPS exposure increased phospho-NIK, but not total NIK
Treatment of NCM460 cells with LPS produced no significant changes in total NIK, but phospho-NIK increased from 9.2 ± 0.1% of the total NIK to 36.2 ± 3.0% of the total NIK (p<0.001) ( Fig. 2A) . Bcl10 silencing by siRNA reduced the LPS-induced increase in phospho-NIK to baseline level. The LPS-induced increase in phospho-NIK in the NCM460 cells was totally blocked when the cells were treated with TLR4 blocking antibody for 2 hours before LPS exposure, consistent with LPS activation of the non-canonical pathway through TLR4 (data not shown).
Similarly, in the WT MEF cells, total NIK did not change following exposure to LPS, but phospho-NIK increased from 8.9 ± 0.6% of the total NIK to 32.1 ± 1.7% of the total NIK (Fig.   2B) . Also, in the MEF IKKα -/-cells, phospho-NIK increased from 8.3 ± 0.9% to 30.1 ± 1.9% of the total NIK (Fig. 2C) , and from 9.1 ± 0.8% to 31.0 ± 2.5% of the total NIK in the MEF IKKβ -/-cells (Fig. 2D) . These findings indicate that the LPS-induced increase in phospho-NIK must occur upstream of the IKK signalosome, since phospho-NIK content was unaffected by the presence or absence of IKKα or IKKβ.
Confocal images of total NIK and phospho-NIK following LPS and BCL10 silencing in
NCM460 cells
Confocal microscopy of total NIK (Fig. 3, A-F) and phospho-NIK (Fig. 4, A-F ) in NCM460 cells supported the finding that LPS-induced NIK phosphorylation was BCL10-dependent. Staining for phospho-NIK was absent when BCL10 expression was silenced by specific siRNA. In contrast, total NIK staining did not change after LPS exposure, nor after BCL10 silencing.
Mutation of Serine 138 of BCL10 inhibited LPS-induced increases in Phospho-NIK and
RelB , but not in RelA in NCM460 cells
Silencing BCL10 expression eliminated the LPS-induced increases in phospho-NIK in the NCM460 cells ( Fig. 2A) and in the MEF (Figs. 2B-D) , demonstrating a requirement for
BCL10
. In order to demonstrate how BCL10 might lead to NIK phosphorylation, NCM460 cells were transfected with either wild type BCL10 or BCL10 mutated at Ser138 or at Ser218 and treated with LPS (10 ng/ml x 6 h). Phospho-BCL10 (Ser 138) was measured to determine the effectiveness of the Ser138Gly mutation (Fig. 5A ). When transfected with wild type BCL10 and exposed to LPS, phospho-Ser increased to 7.0 times the control phospho-BCL10 (Ser 138) level.
Cells transfected with the Ser138Gly mutant showed a decline in the measured phospho-BCL10.
In contrast, cells transfected with the Ser218Gly mutant demonstrated an increase in phospho-BCL10 similar to that following transfection with wild type BCL10.
In NCM460 cells transfected with mutated BCL10 (Ser138Gly), no increase in phospho-NIK occurred, in contrast to increases in phospho-NIK in cells transfected with either wild type BCL10 (to 376 ± 27% of the baseline) or the Ser218Gly mutant (to 413 ± 18% of the baseline) (Fig. 5B) . These findings indicate a selective effect of BCL10 Ser138 on NIK phosphorylation and, thereby, on the non-canonical pathway.
LPS treatment of NCM460 cells transfected with either wild type or mutated BCL10
produced an increase in nuclear RelA in the cells transfected with wild type BCL10 to 3.9 ± 0.1 times the baseline (Fig. 5C) .RelA increased to ~2 times the baseline value in the cells transfected with either the Ser138Gly (to 2.2 ± 0.3) or Ser218Gly (to 2.0 ± 0.2) mutants. These findings demonstrate the importance of both Ser138 and Ser218 in the activation of RelA.
In contrast, LPS produced a smaller increase in RelB, and this increase was completely absent in the Ser138Gly mutant cells (Fig. 5D) . Nuclear RelB in the NCM460 cells transfected with either wild type BCL10 or the Ser218Gly mutant increased to ~1.8 times the baseline level.
These findings are consistent with the impact of the Ser138Gly mutation on phospho-NIK, and on activation of the non-canonical pathway.
BCL10 mutations or silencing reduced the LPS-induced increases of phospho-IκBα and IL-8 or KC
NCM460 cells transfected with either wild type or Ser138 or Ser218 mutant BCL10 were treated with LPS, and the phospho-IκBα content (Fig. 6A) and IL-8 secretion ( reported [24] , and it was concluded that LPS was not associated with activation of the noncanonical pathway. However, other reports suggested that LPS did activate the non-canonical pathway [31, 32] . Our results demonstrate no increase in total NIK, but indicate that LPS can activate the non-canonical pathway by phosphorylation of NIK, and that this phosphorylation requires prior phosphorylation of Ser138 of BCL10. The pathways are depicted in Figure 7 , and resemble the recently reported carrageenan-associated pathways [29] . Importantly, additional findings in this report specify the effects of distinct mutations in BCL10 on LPS-induced effects involving phospho-NIK, RelA, RelB, IL-8, and phospho-IκBα.
Activation of NIK by phosphorylation has been reported in other studies [33, 34] . These By induction of both the canonical and noncanonical pathways of NF-κB activation, LPS influences a wider range of NF-κB transcriptional events [35] [36] [37] . LPS is one of the few known inducers of both the noncanonical and canonical pathways of NF-κB activation, a group that includes lymphotoxin, B-cell activating factor (BAFF), and carrageenan [20, 38, 39] . This study, to the best of our knowledge, is the first report of a mechanism by which LPS activates the noncanonical pathway in non-myeloid cells.
The non-canonical pathway of NF-κB has been identified as an alternate route by which transcription of genes involved in inflammation can be regulated. Reports have suggested complex feedback between the canonical and non-canonical pathways and the potential of the non-canonical pathway to provide a more sustained activation of specific genes [35] [36] [37] . Hence, the ability of LPS to activate both RelA and RelB confers additional avenues by which the impact of LPS exposure on vital cellular processes can be transmitted. Also, demonstration that BCL10 is involved in both canonical and non-canonical pathways increases considerations about the important role of BCL10 in mediating inflammation and the innate immune response [40] .
LPS is a significant source of clinical morbidity and mortality owing to its role in the etiology of systemic inflammatory response syndrome (SIRS) and sepsis. Although silencing.
In the images, green represents phalloidin-stained β-actin, red is total NIK, and blue is DAPI- In the images of phospho-NIK (A-F), phalloidin-actin is stained green, DNA is stained blue, and phospho-NIK is stained red by Alexa-Fluor dyes, as described in the Methods. A, C, and E demonstrate staining for phospho-NIK; B, D, and F are the merged images.
A,B.
No staining for phospho-NIK was seen in the control cells.
C,D.
Following LPS exposure and control siRNA, phospho-NIK staining was increased significantly.
E,F.
Following BCL10 silencing and LPS exposure, no staining for phospho-NIK was evident. 
